This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 955756.

ESR3 and ESR12 join the team

Two more Early Stage Researchers (ESRs) have started working as part of the  InPharma consortium. Nicolas (ESR3) and Malte (ESR12). Further details on their individual research and their fellow ESRs can be found in the ESR profiles.

Nicolas Pätzmann ist working at Zentivia as ESR 3. His research project will focus on computational tools to predict co-grinding approaches to overcome dissolution rate limited absorption.

Malte Senniksen has started working at Fraunhofer in Germany and will spend part of his individual project at Roche in Switzerland. His research project will focus on the application of an end–to-end, animal-free modelling approach to the development of enabling drug products: focus on amorphous solid dispersions (ASD).